Serum Institute of India wants Emergency use Authorization from DCGI

New Delhi, 6/12: The Serum Institute of India(SII) on Sunday applied to the Drugs Controller General of India (DCGI) to seek emergency authorization for CovidShield India.

The SII is currently conducting phase-three trials of the Oxford-AstraZeneca vaccine candidate in different parts of the country. It is co-sponsored by the Indian Council of Medical Research (ICMR).

The Serum Institute of India is the second company with a COVID-19 vaccine candidate to seek emergency use authorization from the DCGI in India. Previusly, Pfizer was the first to seek emergency use authorization from the DGCA for its COVID-19 vaccine in India.